Biotech News

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

RxSight (RXST)RxSight2026-08-05 20:05 ESTEarnings

ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook. Second Quarter 2026 Highlights Total company Q2 revenue of $33.7 million, which includes

Related news

RXSTRxSight2026-07-06 20:15 EST

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

SHCSotera Health2026-08-06 11:00 EST

Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook

PAVMPAVmed2026-08-14 12:00 EST

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

PAVMPAVmed2026-08-13 12:00 EST

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

ICUSeaStar Medical2026-08-12 20:05 EST

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

STIMNeuronetics2026-08-11 11:50 EST

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

ICUIICU Medical2026-08-06 20:05 EST

ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance

PLSEPulse Biosciences2026-08-06 20:05 EST

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

View all latest news

RxSight

Adjustable Cataract Lenses RxSight is an ophthalmic medical-device company focused on customized vision after cataract surgery. Light Adjustable Lens System The system combines an implantable Light Adjustable Lens with a Light Delivery Device. After surgery, physicians use ultraviolet light treatments to modify the lens and refine the...

Recent company news

RXSTRxSight2026-08-26 20:15 EST

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

RXSTRxSight2026-08-05 20:05 EST

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

RXSTRxSight2026-07-26 20:00 EST

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

RXSTRxSight2026-07-15 20:15 EST

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RXSTRxSight2026-07-06 20:16 EST

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

Stock data

Close: 5.20 USD
Market cap: 204.5M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States